2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Marcus & Millichap reported third quarter 2026 revenue of $208.4 million, up 7.5% from a year earlier, and net income of $1.0 million, or $0.03 per diluted share, compared with $0.2 million, or $0.01, in the third quarter of 2025. The company said the results are preliminary until it files its Form 10-Q, and it expects near-term challenges in the commercial real estate market to extend through 2026.
Total revenue was $208.4 million versus $193.9 million; brokerage commissions rose 7.4% to $174.1 million, with Middle Market and Larger Transaction Market brokerage revenue up 18.1%.
Adjusted EBITDA was $8.2 million versus $6.9 million; cost of services rose to 64.0% of total revenue, up 160 basis points.
Nine-month revenue was $582.8 million, up 14.0%, and nine-month net income was $1.8 million, or $0.05 per diluted share, compared with a net loss of $15.2 million.
The company repurchased 912,957 shares for $23.9 million in the first nine months and had about $90.1 million remaining under its repurchase program as of November 3, 2026.
Ziff Davis reported unaudited third quarter 2026 results, with revenue down 5.6% from a year earlier and a swing to an operating loss of $33.6 million, including a $29.6 million goodwill impairment. Adjusted diluted EPS was $1.39 versus $1.40 a year earlier, and the company repurchased $92.0 million of its shares during the quarter. The company will discuss the results on a call on November 6, 2026.
Revenue was $289.3 million versus $306.5 million in Q3 2025; adjusted EBITDA was $82.2 million versus $97.8 million.
Net loss from continuing operations was $28.7 million, or $0.85 per diluted share, compared with a loss of $16.0 million, or $0.39 per share, in Q3 2025.
Adjusted diluted EPS was $1.39 compared with $1.40 a year earlier.
Share repurchases totaled $92.0 million in Q3 2026 and approximately $265 million for the first three quarters of 2026.
Revelation Biosciences reported results for the three and nine months ended September 30, 2026, with no revenue line in the filing. The net loss grew from a year earlier, and cash fell from $10.7 million at December 31, 2025 to $9.1 million, which the company says will fund operations into the second quarter of 2027.
Net loss for the three months ended September 30, 2026 was $3.3 million, compared with $1.9 million a year earlier.
Net loss for the nine months ended September 30, 2026 was $9.6 million, compared with $6.4 million a year earlier.
Cash and cash equivalents were $9.1 million at September 30, 2026, versus $10.7 million at December 31, 2025; the company expects this to fund operations into the second quarter of 2027.
Net cash used for operating activities was $2.6 million for the third quarter of 2026, compared with $1.6 million in the same period of 2025.
Avalanche Treasury Corp (AVAT) reported preliminary, unaudited third-quarter 2026 net income of approximately $54.6 million, or $1.53 per diluted share, with about $60 million from market-driven changes in the value of its AVAX holdings and realized losses. It also repurchased about 8% of its Class A shares at an average price of $1.14 and repaid its FalconX loan in full, and the full third-quarter results are due in November 2026.
Preliminary Q3 2026 net income of approximately $54.6 million, or $1.53 per diluted share; approximately $60 million of gains from market-driven changes in AVAX value and realized losses
Repurchased 2,889,440 Class A shares at an average of $1.14 per share, about $3.3 million in total, roughly 8% of Class A shares outstanding as of August 24, 2026
Held 13.31 million AVAX tokens as of September 30, 2026, with about 60% unlocked; about 91% was staked in September 2026
Conference call on November 19, 2026 at 4:00 p.m. ET to discuss third-quarter results
Mount Logan Capital reported third-quarter 2026 total revenues of $12.9 million, up 12% from $11.4 million a year earlier, and a net loss of $3.7 million versus $13.4 million in the third quarter of 2025. Basic loss per share was $0.33, compared with $1.64, and the company attributed the narrower loss mainly to transaction expenses from the prior-year TURN merger that did not recur. Segment Income fell to $3.2 million in the quarter, but year-to-date Segment Income rose 21% to $11.5 million.
Total revenues $12.9 million for Q3 2026, up 12% from $11.4 million in Q3 2025
Net loss $3.7 million, compared with $13.4 million in Q3 2025; basic loss per share $0.33 versus $1.64
Q3 Segment Income $3.2 million versus $4.2 million; year-to-date Segment Income $11.5 million, up 21%
Quarterly distribution of $0.03 per share payable November 30, 2026 to holders of record on November 19, 2026
Comstock reported third-quarter 2026 revenue of $17.9 million, up 34% from a year earlier, and net income of $0.6 million, up 9%. Adjusted EBITDA more than doubled to $2.3 million, although the quarter included a $1.0 million unrealized loss on its Jericho Energy Ventures equity investments. Headline revenue and profit measures improved for both the quarter and the first nine months, but the quarter's net income absorbed that investment loss.
Q3 2026 revenue was $17.9 million versus $13.3 million in Q3 2025; Adjusted EBITDA was $2.3 million versus $1.1 million.
Q3 diluted EPS was $0.06 versus $0.05; year-to-date diluted EPS was $1.05 versus $0.34, with year-to-date net income of $11.4 million.
Q3 net income includes a $1.0 million unrealized loss on Jericho (JEV) equity investments, which partially reverses a significant Q2 gain; the year-to-date gain remains up $3.7 million.
Managed portfolio grew to 115 assets, up from 91 a year earlier, including 12 new ParkX contracts in Q3.
Regency Centers reported third quarter 2026 net income attributable to common shareholders of $75.1 million, or $0.41 per diluted share, alongside Nareit FFO of $1.23 per diluted share. The company raised its full-year 2026 Core Operating Earnings guidance midpoint and increased its quarterly common stock dividend by 6% to $0.800 per share. Shareholders experienced higher year-over-year Same Property NOI growth and strong leasing spreads during the quarter.
Reported Q3 2026 Net Income Attributable to Common Shareholders of $75.1 million, or $0.41 per diluted share.
Raised full year 2026 Core Operating Earnings guidance range to $4.65 to $4.67 per diluted share.
Increased quarterly common stock cash dividend by 6% to $0.800 per share.
Same Property NOI increased year-over-year by 5.1% for the third quarter of 2026.
Tianci International reported fiscal 2026 results for the year ended July 31, 2026, in Exhibit 99.1 to this 8-K. Total revenue rose to $14,242,611 from $9,282,997, helped by $4,409,563 in first-year mineral sales, and the net loss narrowed to $2,454,798 from $2,686,357. Logistics revenue fell 0.7% and its gross profit percentage dropped to 2.29%, so the core business weakened even as total results improved.
Total revenue of $14,242,611 for the year ended July 31, 2026, versus $9,282,997 a year earlier.
Mineral sales, a new business, contributed $4,409,563 at a 7.43% gross profit percentage.
Net loss of $2,454,798 versus $2,686,357 in fiscal 2025; operations used $2,199,382 in cash.
A public offering completed in June 2026 produced net proceeds of $4,390,512.
Brighthouse Financial reported third quarter 2026 net income available to shareholders of $302 million, or $5.21 per diluted share, down from $453 million, or $7.89 per share, a year earlier. Adjusted earnings fell to $527 million, or $9.12 per share, from $970 million, or $16.87 per share, though the company said its annual actuarial review added $314 million of net favorable notable items. The company also said regulatory approvals for the pending $70.00 per share Aquarian Capital acquisition are not expected before the December 6, 2026 Outside Date, and the parties are discussing an extension.
Net income available to shareholders was $302 million, or $5.21 per diluted share, versus $453 million, or $7.89 per share, in the third quarter of 2025.
Adjusted earnings, less notable items, were $213 million, or $3.68 per diluted share, versus $261 million, or $4.54 per share, a year earlier.
Annuity sales were $2.4 billion, including $2.1 billion of Shield Level Annuities, with annuity sales down 12% quarter-over-quarter.
The merger agreement's Outside Date is December 6, 2026; the company and Aquarian Capital are discussing an extension, with no assurance of agreement.
LCI Industries reported third-quarter 2026 results on a call furnished in an 8-K. Net sales were just under $1 billion, down 4% from a year earlier, while adjusted diluted EPS rose to $2.21 from $1.97 and GAAP diluted EPS was $2.05. The company narrowed its full-year adjusted EPS outlook to $8.25 to $8.50 and said the proposed merger with Patrick Industries remains pending.
Q3 2026 net sales were just under $1 billion, down 4% year over year, mainly due to lower North American RV wholesale shipments.
Adjusted diluted EPS was $2.21 versus $1.97 a year earlier; GAAP net income was $50 million, or $2.05 per diluted share.
Full-year 2026 adjusted EPS range was tightened to $8.25 to $8.50; adjusted revenue is expected at $3.9 billion to $4 billion.
The company said it declined a Monomoy Capital proposal because its board judged it not superior to the proposed merger with Patrick Industries.
Tucows reported third-quarter 2026 revenue of $100.0 million, up 1.4% from a year earlier, and a net loss of $10.3 million, down from $23.0 million in the third quarter of 2025. Gross profit and Adjusted EBITDA rose, but the company said gross profit was driven mainly by a large, non-recurring rate adjustment from renegotiating its mobile contract, and cash and restricted cash fell to $41.0 million from $60.2 million at the end of the second quarter.
Revenue of $100.0 million, up 1.4% year over year, driven by revenue growth at Ting.
Net loss of $10.3 million, or $(0.92) per share, versus a net loss of $23.0 million, or $(2.08) per share, in Q3 2025.
Adjusted EBITDA of $18.6 million, up 39.8% year over year, mainly due to the mobile contract re-rate in the Corporate segment.
Cash and restricted cash of $41.0 million at September 30, 2026, down from $60.2 million at June 30, 2026.
Ready Capital reported a third-quarter 2026 GAAP net loss of $62.2 million, or $(0.40) per share, compared with a net loss of $16.7 million, or $(0.13) per share, a year earlier. Distributable loss was $(0.53) per share, and the company declared $0.01 per common share in dividends, down from $0.125 a year earlier, which matters to shareholders because it reflects weaker earnings and a much smaller dividend.
Q3 2026 GAAP loss per common share of $(0.40), versus $(0.13) in Q3 2025; nine-month loss per share of $(2.27)
Distributable loss per common share of $(0.53); before realized losses, $(0.21)
Dividends declared per common share of $0.01 in Q3 2026, versus $0.125 in Q3 2025
Book value of $6.44 per common share as of September 30, 2026; cash of $157 million and total leverage of 2.8x
Diodes reported third quarter 2026 revenue of $532.6 million, up 35.8% from a year earlier, with GAAP net income of $43.7 million, or $0.95 per diluted share, versus $0.31 a year earlier. The company expects fourth quarter revenue of about $550 million, plus or minus 3%, and non-GAAP adjusted EPS of $1.35, plus or minus $0.10. The results are preliminary and unaudited and remain subject to revision until the Form 10-Q is filed.
Q3 2026 revenue $532.6 million, up 35.8% from $392.2 million in Q3 2025
GAAP EPS $0.95 per diluted share vs $0.31 in Q3 2025; non-GAAP EPS $1.18 vs $0.37
Q4 2026 outlook: revenue about $550 million (plus or minus 3%); non-GAAP EPS $1.35 (plus or minus $0.10)
Private placement of 0.00% Convertible Senior Notes due 2031 totaling $375 million
PLAYSTUDIOS reported third-quarter 2026 revenue of $48.9 million, down from $57.6 million a year earlier, and a net loss of $11.0 million, up from $9.1 million. The company discontinued two products, Tetris Block Party and The Win Zone, and recorded $6.7 million in non-cash impairment charges plus a $9.2 million goodwill impairment. It is not providing formal financial guidance, which leaves shareholders without a forward outlook.
Q3 2026 revenue was $48.9 million versus $57.6 million in Q3 2025; direct-to-consumer revenue rose 108% to $16.0 million.
Net loss was $11.0 million versus $9.1 million; Consolidated AEBITDA rose to $10.0 million from $7.2 million.
Goodwill impairment of $9.2 million and a $6.7 million non-cash impairment charge tied to the discontinued products.
No formal financial guidance was provided; restructuring annualized savings range was raised to $37.0 million to $39.0 million, with $44.6 million left on the share repurchase authorization.
VAALCO reported a third-quarter 2026 net loss of $39.8 million ($0.38 per diluted share), compared with net income of $42.4 million in the second quarter, mainly due to $34.7 million of unrealized hedging losses. Net revenue and Adjusted EBITDAX both rose from the second quarter, and the company gave fourth-quarter 2026 sales volume and capital spending guidance.
Q3 2026 net loss of $39.8 million ($0.38 per diluted share) versus Q2 2026 net income of $42.4 million
Net revenue of $147.0 million, up 9% from Q2 2026; Adjusted EBITDAX up 30% to $71.1 million
Q4 2026 guidance: NRI sales volumes of 20,800 to 22,600 BOPD and capital expenditures of $55 million to $75 million
Quarterly dividend of $0.0625 per share payable December 22, 2026; conference call November 6, 2026 at 8:00 a.m. Central Time
Strawberry Fields REIT reported third-quarter 2026 results that were pulled down by a $24.6 million foreign currency transaction loss tied to the retirement of Bond Series A, C and D. Net loss was $14.8 million and FFO was negative $3.6 million, compared with net income of $8.9 million and FFO of $20.7 million a year earlier. AFFO, which excludes that loss, rose to $18.8 million, or $0.34 per share, from $18.1 million, or $0.33 per share.
Q3 2026 net loss of $14.8 million vs. net income of $8.9 million in Q3 2025
Q3 2026 FFO of negative $3.6 million ($0.65 per share loss) vs. $20.7 million ($0.37 per share) a year earlier
Q3 2026 AFFO of $18.8 million ($0.34 per share), up from $18.1 million ($0.33 per share)
Subsequent to quarter end on November 1, 2026, the company agreed to buy a 99-bed skilled nursing facility in Angola, Indiana for $15 million
NeOnc reported third-quarter 2026 results, with its net loss falling to $4.4 million from $8.6 million in the year-earlier quarter and total operating expenses declining to $5.8 million from $6.9 million. Cash and cash equivalents rose to $6.2 million at September 30, 2026, helped by a September registered direct offering of approximately $15 million gross, and the company said it will present NEO100 and NEO212 data on November 13, 2026.
Net loss attributable to common stockholders was $7.3 million, or $(0.28) per share, versus $8.6 million, or $(0.45) per share, in Q3 2025; the figure includes $2.8 million of noncash deemed dividends.
Cash and cash equivalents were approximately $6.2 million at September 30, 2026, up from approximately $2.0 million at June 30, 2026.
R&D expenses were $1.3 million, compared with $0.7 million in Q3 2025, while G&A expenses fell to $0.6 million from $0.9 million.
Data from NEO100 and NEO212 will be presented in two posters on November 13, 2026, at the Society for Neuro-Oncology Annual Meeting in Philadelphia.
PodcastOne said it expects record first-half revenue of $31.5 million and Adjusted EBITDA of $3.0 million, up 76% year over year, for the six months ended September 30, 2026. Second-quarter revenue is expected to be $15.2 million with Adjusted EBITDA of $1.4 million. These figures are preliminary, unaudited and subject to change, and the company's board has formed a special committee to evaluate inbound strategic interest, which may or may not lead to a transaction.
Expected first-half revenue of $31.5 million and Adjusted EBITDA of $3.0 million, up 76% year over year
Expected second-quarter revenue of $15.2 million and Adjusted EBITDA of $1.4 million
Special committee of independent directors formed after inbound interest from multiple strategic parties, first announced October 28; company intends to retain a financial advisor
Figures are preliminary and unaudited, not reviewed by MGO; no GAAP net income reconciliation was provided
Helios Technologies reported third-quarter 2026 net sales of $230 million, up 4% from the prior-year period, and GAAP diluted EPS of $0.53, up 71% from $0.31. The company raised its full-year 2026 sales outlook to $895 million to $902 million from $880 million to $900 million, while narrowing its adjusted EBITDA margin and adjusted diluted EPS ranges.
Q3 2026 net sales were $229.7 million, up 4%; the company cited 13% growth on a pro forma basis
Q3 GAAP diluted EPS was $0.53 versus $0.31; adjusted diluted EPS was $0.80, up 11%
FY2026 sales outlook raised to $895 million to $902 million; adjusted diluted EPS range narrowed to $3.08 to $3.15
Q4 2026 outlook: sales of $205 million to $212 million and adjusted diluted EPS of $0.60 to $0.67
Turtle Beach reported third-quarter 2026 net revenue of $84.7 million, up 5.3% from $80.5 million a year earlier, and net income of $4.4 million versus $1.7 million. The company reaffirmed its full-year 2026 net revenue guidance of $335 million to $355 million and adjusted EBITDA guidance of $44 million to $48 million, and said it expects capacity to resume share repurchases after the holiday season.
Q3 net revenue was $84.7 million, up 5.3% from $80.5 million; diluted EPS was $0.24 versus $0.08
Adjusted EBITDA was $8.1 million versus $11.0 million a year earlier; gross margin was 34.9%
Full-year 2026 guidance reaffirmed: net revenue $335 million to $355 million, adjusted EBITDA $44 million to $48 million
Nine-month net loss was $18.1 million; inventory rose to $79.8 million, up $23.2 million from the second quarter
Hyperliquid Strategies Inc (PURR) reported net income of $620.6 million for the quarter ended September 30, 2026. The filing says most of that figure came from $803.0 million in net unrealized gains on its HYPE token holdings, and it also included a $172.3 million income tax provision. The company also said it raised $911 million in equity and deployed $802 million, mainly to buy HYPE tokens, and that it has filed an application to become a futures commission merchant.
Net income of $620.6 million for the quarter, including $803.0 million in net unrealized gains on HYPE tokens and a $172.3 million provision for income taxes
Quarter-end HYPE holdings of 38.5 million tokens, up from 29.3 million at June 30, 2026, after 9.1 million tokens were bought for $785 million
Raised $911 million under its committed equity facility and reported $254.6 million in cash and cash-like instruments with zero debt
Stockholders approved on November 4, 2026 the issuance of shares under the ChEF Purchase Agreement above 19.99% of common stock, with 81,436,539 votes for
Athene Holding furnished its third-quarter 2026 financial supplement, showing a GAAP net loss available to common stockholder of $1,158 million, compared with net income of $1,223 million a year earlier. Spread related earnings, the company's management measure, fell 3% to $844 million, but rose 7% to $909 million excluding notable items, and the filing says the GAAP loss was tied to large investment and market risk benefit swings. Shareholders face a larger GAAP loss and lower stockholders' equity, while the underlying spread measure was mixed.
GAAP net loss available to Athene common stockholder of $1,158 million in 3Q'26, versus net income of $1,223 million in 3Q'25
Spread related earnings of $844 million, down 3% year over year; excluding notable items, $909 million, up 7%
Total revenues of $3,065 million versus $7,998 million a year earlier, with investment related losses of $3,418 million
Total Athene Holding stockholders' equity was $13,413 million at September 30, 2026, down from $20,492 million at December 31, 2025
Pangaea Logistics Solutions reported third-quarter 2026 results, with GAAP net income attributable to the company of $38.3 million, or $0.59 per share, up from $12.2 million, or $0.19 per share, a year earlier. Total revenue was $219.1 million, and Adjusted EBITDA rose 81.3% to $52.4 million, which matters to shareholders because it shows a large year-over-year gain in earnings and cash generation. The board also declared a $0.10 quarterly dividend.
GAAP net income attributable to Pangaea of $38.3 million, or $0.59 per share, versus $12.2 million, or $0.19 per share, in Q3 2025
Total revenue of $219.1 million versus $168.7 million in Q3 2025; Adjusted EBITDA of $52.4 million, a 23.9% margin versus 17.1%
Average TCE rate of $20,414 per day versus $15,559 per day a year earlier; the company reported cash and equivalents of $144.9 million at September 30, 2026
Quarterly dividend of $0.10 per share, payable December 15, 2026, to holders of record on December 1, 2026
BRT Apartments reported a wider net loss for the third quarter ended September 30, 2026, with a loss of $0.23 per diluted share versus $0.14 a year earlier. Funds from operations (FFO) and adjusted FFO (AFFO) per diluted share also declined, to $0.26 and $0.31 from $0.28 and $0.36, and combined portfolio net operating income slipped to $15.1 million from $15.3 million. The company declared a $0.25 per share dividend for the quarter.
Net loss attributable to common stockholders was $3.955 million, or $0.23 per diluted share, for Q3 2026, versus $2.707 million, or $0.14, in Q3 2025.
FFO per diluted share was $0.26, down from $0.28; AFFO per diluted share was $0.31, down from $0.36.
Combined portfolio NOI was $15.1 million for Q3 2026 compared with $15.3 million a year earlier.
A $0.25 per share dividend was declared for the third quarter of 2026.
Friedman Industries reported record second-quarter results for the period ended September 30, 2026, with net earnings of $15.6 million on net sales of $286.8 million, versus $2.2 million and $152.4 million a year earlier. The company also recorded a $14.6 million hedging charge in the quarter, of which $9.8 million is unrealized, a charge close in size to the quarter's net earnings.
Net earnings of $15.6 million ($2.19 diluted EPS) vs. $2.2 million ($0.32) in the prior-year quarter
Net sales of $286.8 million, up from $152.4 million; sales volume of about 219,500 tons, up 23%
$14.6 million hedging charge in the quarter, including $9.8 million unrealized on open metal positions
Management expects third-quarter sales volume consistent with seasonal trends and sequential margin improvement
Consolidated Edison reported third-quarter 2026 net income of $766 million, or $2.07 per share, up from $688 million, or $1.91 per share, in the third quarter of 2025. The company also narrowed its full-year 2026 adjusted earnings per share guidance range to between $6.05 and $6.15.
Q3 2026 net income was $766 million ($2.07 per share) compared to $688 million ($1.91 per share) in Q3 2025.
First nine months of 2026 net income reached $1,998 million ($5.44 per share) versus $1,726 million ($4.84 per share) for the same period in 2025.
Full-year 2026 adjusted EPS guidance was narrowed to a range of $6.05 to $6.15 per share.
The company plans to invest approximately $797 million in climate resilience from 2026 through 2030.
Chesapeake Utilities reported third-quarter 2026 net income of $21.6 million, or $0.89 per diluted share, up from $19.4 million, or $0.82, a year earlier. The company also reaffirmed its 2026 capital expenditure guidance and its 2028 earnings guidance of $7.75 to $8.00 per share, and said it will joint venture 49 percent of the $1.2 billion Florida Energy Pathway project with NextEra Energy Resources. Shareholders may be affected by the planned equity program of up to $225 million.
Q3 2026 operating revenues were $195.8 million, up from $179.6 million; net income was $21.6 million versus $19.4 million
Nine-month 2026 diluted EPS was $4.40, up from $4.03 a year earlier
Joint venture with NextEra Energy Resources to finance and own 49 percent of the $1.2 billion, 97-mile Florida Energy Pathway project
New at-the-market equity program allows issuance and sale of up to $225 million of common stock; 2026 capital expenditure guidance of $550 to $600 million affirmed
Cedar Realty Trust filed an 8-K furnishing information made available by its parent, Wheeler Real Estate Investment Trust (WHLR), on November 5, 2026. The filing includes a WHLR press release and supplemental financial information for the three and nine months ended September 30, 2026, but the 8-K itself does not state any revenue, profit, or guidance figures.
Filing dated November 5, 2026, signed by CEO and President M. Andrew Franklin
Exhibits 99.1 (WHLR press release) and 99.2 (supplemental financial information) cover the three and nine months ended September 30, 2026
Materials are on WHLR's website, www.whlr.us, and the filing says that website is not incorporated into the 8-K
MSC Income Fund reported third quarter 2026 total investment income of $35.5 million, up $0.2 million from a year earlier, while net investment income fell 13% to $14.4 million, or $0.32 per share. Net increase in net assets from operations dropped 32% to $18.1 million, and net asset value rose to $16.56 per share from $16.51 at June 30, 2026, and $15.85 at December 31, 2025. Nick Meserve is set to become CEO effective November 9, 2026, as previously announced in June.
Net investment income was $14.4 million, or $0.32 per share, versus $16.6 million, or $0.35 per share, in Q3 2025.
Total investment income was $35.5 million, compared with $35.4 million in Q3 2025.
Net asset value was $16.56 per share as of September 30, 2026, up from $16.51 at June 30, 2026.
Nick Meserve will transition to CEO effective November 9, 2026, with Dwayne L. Hyzak continuing as Executive Chairman.
SUI Group Holdings reported third-quarter 2026 net income of $47.7 million, or $0.59 per diluted share, compared with a net loss of $44.3 million a year earlier. The result was driven mainly by $82.7 million in unrealized gains on digital assets, while revenue fell, and the company's revenue and other income excluding investment gains and losses was $557,000 against $2.6 million a year earlier.
Q3 2026 net income was $47.7 million ($0.59 per diluted share), versus a net loss of $44.3 million ($0.72 per share) in Q3 2025.
Digital asset results included $82.7 million in net unrealized gains and $28.0 million in realized losses, which the company said mainly reflect U.S. GAAP treatment and SUI's market price.
Total revenue and other income excluding investment gains and losses fell to $557,000 from $2.6 million, mainly due to lower legacy loan income and lower SUI staking revenue.
As of November 2, 2026, the company held 109,290,995 SUI, including 6,000,000 SUI loan receivables, and reported an mNAV of 0.72x.
Nkarta reported third-quarter 2026 results, with a net loss of $33.3 million, or $0.45 per share, compared with a net loss of $21.7 million, or $0.29 per share, a year earlier. The company said its $216.0 million in cash, cash equivalents, restricted cash and investments as of September 30, 2026, is expected to fund operations into 2029. Higher research and development spending drove the larger loss, and shareholders face continued losses while the company's lead candidate is still in clinical trials.
Q3 2026 net loss of $33.3 million ($0.45 per share), up from $21.7 million ($0.29 per share) in Q3 2025
R&D expenses rose to $29.5 million from $20.2 million; G&A expenses fell to $6.3 million from $7.1 million
Cash and investments were $216.0 million on September 30, 2026, down from $295.1 million on December 31, 2025
Initial NKX019 clinical data to be presented at ACR Convergence 2026, with an oral presentation on November 8
Concentra Group Holdings Parent, Inc. reported its third quarter 2026 financial results, highlighting an 8.6% increase in revenue to $622.1 million and a 36.0% increase in net income to $67.8 million compared to the same period in 2025. Driven by this performance, the company raised its full-year 2026 financial guidance, declared a cash dividend of $0.0625 per share, and authorized a new $250 million share repurchase program.
Revenue for the third quarter of 2026 reached $622.1 million, up 8.6% year over year.
Net income for the quarter rose 36.0% to $67.8 million, with basic and diluted earnings per share at $0.52.
The board of directors declared a cash dividend of $0.0625 per share, payable on or about December 4, 2026.
A new share repurchase program was authorized to buy back up to $250 million of outstanding common stock.
Hyster-Yale posted supplemental historical financial data on its website on November 5, 2026, alongside its third quarter 2026 results, in an Exhibit 99 furnished under Items 2.02 and 7.01. The schedules show third quarter 2026 revenue of $827.4 million, down 15.5% from a year earlier, and an operating loss of $9.1 million compared with an operating profit of $2.3 million in the third quarter of 2025.
Q3 2026 revenue of $827.4 million, down 15.5% from $979.1 million in Q3 2025
Q3 2026 gross profit of $124.1 million, or 15.0% of revenue
Q3 2026 operating loss of $9.1 million vs. operating profit of $2.3 million in Q3 2025; net loss attributable to stockholders of $14.9 million vs. $2.3 million a year earlier
Q3 2026 restructuring charges of $1.5 million, all in the Americas segment
BioAge Labs reported third quarter 2026 results on November 5, 2026. Collaboration revenue fell to $0.3 million from $2.1 million, and the net loss widened to $33.5 million, or $0.73 per share, from $20.2 million, or $0.56 per share, a year earlier, mainly due to clinical trial costs for BGE-102. The company had about $352.3 million in cash, cash equivalents and marketable securities, which it says will fund operations through 2029.
Net loss was $33.5 million ($0.73 per share) for the quarter ended September 30, 2026, versus $20.2 million ($0.56 per share) a year earlier.
Research and development expenses rose to $30.2 million from $18.5 million, driven by a $13.2 million increase in BGE-102 direct costs tied to the QUELL-CV and QUELL-DME trials.
Collaboration revenue was $0.3 million, down from $2.1 million, mainly due to a $1.7 million cumulative catch-up adjustment tied to a September 2026 Novartis agreement amendment.
Cash, cash equivalents and marketable securities totaled about $352.3 million as of September 30, 2026; QUELL-CV topline data are expected in the fourth quarter of 2026.
Ameren Corporation announced its third quarter 2026 financial results, reporting a GAAP diluted EPS of $2.42 compared to $2.35 for the same period in 2025. Driven by strong year-to-date performance and infrastructure investments, the company raised its 2026 earnings guidance range and established its 2027 outlook.
Third quarter 2026 GAAP diluted EPS was $2.42 versus $2.35 in the third quarter of 2025.
Raised 2026 earnings guidance range to $5.35 to $5.55 per diluted share.
Established 2027 earnings guidance range of $5.70 to $5.90 per diluted share.
Planned infrastructure investments of $38.1 billion to support projected rate base growth through 2031.
Kayne Anderson BDC reported third quarter 2026 net investment income of $30.2 million, or $0.46 per share, up from $0.42 in the second quarter. Net asset value per share fell to $15.71 from $16.00, and net earnings dropped to $0.10 per share after a $14.9 million realized loss tied to the restructuring of American Soccer Company (Score) and net unrealized losses. The company also declared a $0.40 per share fourth quarter dividend.
Net investment income of $30.2 million, or $0.46 per share, versus $27.5 million, or $0.42 per share, in Q2 2026
Net asset value per share of $15.71 at September 30, 2026, down from $16.00 at June 30, 2026
Earnings per share of $0.10 versus $0.16 in Q2 2026, reflecting a $14.9 million realized loss on Score and net unrealized losses of $8.5 million
Fourth quarter dividend of $0.40 per share, payable January 19, 2027, to holders of record as of December 31, 2026
Mettler-Toledo International Inc. reported third quarter 2026 net sales of $1.094 billion, representing a 6% increase compared to the prior-year period. Diluted earnings per share rose to $12.29 from $10.57, while adjusted EPS grew 13% to $12.57, driven by improving market demand and solid execution. Management also raised its full-year 2026 adjusted EPS guidance range to $47.70 to $47.90.
Reported net sales for the third quarter of 2026 increased 6% to $1.094 billion.
Diluted earnings per share were $12.29, compared with $10.57 in the third quarter of 2025.
Adjusted diluted EPS increased 13% to $12.57 from $11.15 in the prior-year period.
Full-year 2026 adjusted EPS is forecast to be between $47.70 and $47.90.
Hyster-Yale reported third-quarter 2026 revenue of $827.4 million, down 15% from a year earlier but up 2% from the prior quarter, with a net loss of $14.9 million compared with a $2.3 million loss in Q3 2025. The company expects substantially stronger Q4 2026 results, with adjusted net income returning to positive, and launched cost-reduction programs targeting at least $100 million of annual savings at maturity, with implementation costs of at least $50 million.
Q3 2026 revenue was $827.4 million, down from $979.1 million in Q3 2025 and up from $812.9 million in Q2 2026.
Net loss was $14.9 million, or $0.83 per diluted share, versus a $2.3 million loss in Q3 2025; adjusted diluted loss was $0.77 per share.
Lift Truck bookings rose 45% year over year to $550 million, and unit backlog reached $1.6 billion.
New programs target at least $100 million of annual cost savings at maturity in 2029, with implementation costs of at least $50 million; 2026 capital expenditures are expected at $50 million to $60 million.
Monster Beverage Corporation reported third quarter net sales of $2.56 billion, representing a 16.7 percent increase compared to the same period in 2025. Net income for the quarter rose 8.4 percent to $568.4 million, or $0.29 per diluted share.
Net sales increased 16.7 percent to $2.56 billion for the third quarter ended September 30, 2026.
Net income grew 8.4 percent to $568.4 million, with diluted earnings per share at $0.29.
International net sales increased 28.1 percent to $1.20 billion, representing 47 percent of total net sales.
The company repurchased approximately 2.3 million shares for $100.0 million during the third quarter.
eGain reported fiscal first-quarter 2027 results for the quarter ended September 30, 2026. Total revenue was $21.9 million, down 7% from a year earlier, though the company said it was above the high end of its guidance. GAAP net income fell to $1.6 million, or $0.06 per share, from $2.8 million, or $0.10 per share, and the company reiterated its full-year fiscal 2027 outlook.
Total revenue was $21.9 million, down 7% from $23.5 million a year earlier, and above the high end of company guidance.
GAAP net income was $1.6 million, or $0.06 per share, versus $2.8 million, or $0.10 per share, in Q1 fiscal 2026.
On October 30, 2026, the compensation committee approved fiscal 2026 variable cash pay at 85% of target, including $85,000 for CEO Ashutosh Roy.
Cryoport reported third-quarter 2026 revenue of $50.2 million, up 14% from a year earlier, and raised its full-year 2026 revenue guidance to $197 million to $199 million. The company still posted a wider net loss attributable to common stockholders of $12.9 million, or $0.25 per share, compared with a $8.9 million loss, or $0.18 per share, in the prior-year quarter.
Q3 2026 total revenue was $50.2 million, up 14% year over year; Life Sciences Services rose 18% to $28.6 million.
Full-year 2026 revenue guidance was raised to $197 million to $199 million.
Q3 2026 net loss attributable to common stockholders was $12.9 million, or $0.25 per share, versus $8.9 million, or $0.18 per share, in Q3 2025.
Adjusted EBITDA from continuing operations was $1.1 million for Q3 2026, compared with a negative $0.6 million a year earlier.
Gyre Therapeutics reported third-quarter 2026 revenue of $32.9 million, up 1% from $32.7 million a year earlier, but swung to a net loss of $2.5 million from net income of $1.9 million. The company affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million, while nine-month results showed a larger loss and lower revenue, which matters to shareholders weighing the cost of the Cullgen acquisition and clinical spending.
Q3 2026 revenue was $32.9 million versus $32.7 million in Q3 2025; ETUARY sales were $31.4 million.
Q3 GAAP basic EPS was $(0.04), compared with $0.01 a year earlier.
Nine-month net loss was $35.3 million versus net income of $4.6 million; nine-month revenue was $86.5 million versus $93.0 million.
Total cash, deposits and certificates of deposit were $98.8 million at September 30, 2026, down from $116.1 million at December 31, 2025.
NuScale Power reported results for the quarter ended September 30, 2026, in a press release attached as Exhibit 99.1. Revenue fell to $281,000 from $8.2 million a year earlier because prior-year engineering work for the RoPower project ended, while the net loss narrowed to $45.7 million from $532.6 million, driven by a $491.3 million drop in general and administrative expenses. The company reported $1.9 billion in cash, cash equivalents and investments, and the filing gives no guidance.
Net loss of $45.7 million, or $(0.11) per share, versus a net loss of $532.6 million, or $(1.85) per share, in the year-earlier quarter
Revenue of $281,000 versus $8.2 million, with no comparable Fluor FEED Phase 2 work in 2026
General and administrative expenses of $27.9 million versus $519.2 million; research and development expenses rose to $18.0 million from $11.1 million
Cash, cash equivalents and short- and long-term investments totaled $1.9 billion at September 30, 2026
Red Violet, Inc. reported third quarter 2026 results with revenue up 20% to $27.8 million and net income up 29% to $5.4 million, or $0.35 per diluted share. The company also said operating cash flow reached a record $12.7 million and that it had no debt as of September 30, 2026. The filing contains no guidance changes, and the headline figures all improved year over year.
Revenue rose 20% to $27.8 million; gross margin rose to 76% from 73%.
Net income rose 29% to $5.4 million; diluted EPS was $0.35 versus $0.29 a year earlier.
Closed a public offering with net proceeds of $108.7 million; cash and Treasury holdings totaled $165.7 million with no debt.
Tectonic Therapeutic reported third-quarter 2026 results in an 8-K that furnished its press release. The net loss widened year over year, driven by higher research and development and general and administrative spending, while the company reported favorable Phase 1a safety and pharmacokinetic results for TX2100 and said cash should fund operations into Q1 2029.
Net loss of $21.3 million, or $1.08 per share, for the three months ended September 30, 2026, versus $19.0 million, or $1.02 per share, a year earlier.
Research and development expenses rose to $17.4 million from $16.9 million; general and administrative expenses rose to $6.0 million from $5.0 million.
Cash and cash equivalents were $234.7 million at September 30, 2026, down from $253.8 million at December 31, 2025.
Topline results from the APEX Phase 2 trial of TX45 in PH-HFpEF are expected by the end of January 2027.
Camden Property Trust announced its third quarter 2026 operating results, reporting a diluted EPS of $8.71 primarily driven by a gain on the sale of its California portfolio. The company updated its full-year 2026 earnings guidance and adjusted its same-property growth forecasts.
Diluted EPS for 3Q26 was $8.71, compared to $1.00 in 3Q25.
Core FFO per diluted share for 3Q26 was $1.71, compared to $1.70 in 3Q25.
The company sold its California portfolio for approximately $1.6 billion, recognizing a gain of about $1.0 billion.
Full-year 2026 diluted EPS guidance was revised to a range of $9.42 to $9.46.
nLIGHT reported third quarter 2026 revenue of $73.8 million, up 10.5% from a year earlier, with gross margin of 33.1% versus 31.1%, while its GAAP net loss widened to $7.2 million from $6.9 million. For the fourth quarter, it guided to revenue of $84 million to $90 million, but that range excludes about $15 million of product revenue now expected to ship in the first half of 2027 because of supply chain constraints.
Q3 2026 revenue was $73.8 million versus $66.7 million in Q3 2025, and Adjusted EBITDA was $11.05 million versus $7.1 million.
GAAP net loss was $7.2 million, or $0.12 per diluted share, compared with $6.9 million, or $0.14 per share, in Q3 2025.
Fourth quarter 2026 revenue guidance is $84 million to $90 million, with Adjusted EBITDA guided to $12 million to $18 million.
About $15 million of product revenue expected in Q4 2026 is now expected to be delivered in the first half of 2027.
Horizon Technology Finance reported third quarter 2026 net investment income of $12.3 million, or $0.19 per basic share, down from $14.0 million, or $0.32 per share, a year earlier. The company posted a net decrease in net assets from operations of $28.2 million, or $0.43 per share, compared with a net increase of $30.7 million in the prior-year quarter, and net asset value fell to $5.56 per share from $7.12 a year earlier.
Net investment income of $12.3 million ($0.19 per basic share) vs. $14.0 million ($0.32) in Q3 2025; total investment income was $24.1 million vs. $26.3 million.
Net decrease in net assets from operations of $28.2 million ($0.43 per share), including net unrealized depreciation on investments of $29.1 million.
Net asset value was $5.56 per share at September 30, 2026, vs. $7.12 at September 30, 2025 and $6.98 at December 31, 2025.
Board declared monthly distributions of $0.06 per share for January, February and March 2027, totaling $0.18 per share; Q3 distributions were $0.27 per share.
Xponential Fitness reported third quarter 2026 revenue of $62.3 million, down 21% from a year earlier, and adjusted EBITDA of $24.3 million, down 27%. The company cut its net new studio openings outlook to 124 to 130 from about 150 and narrowed its adjusted EBITDA range to $91.0 million to $94.0 million from $91.0 million to $97.0 million, which lowers the top end, while the Board continues a strategic review that may include a sale of the company.
Q3 2026 revenue was $62.3 million versus $78.8 million; net income was $4.9 million, or $0.10 per basic share, compared with a net loss of $6.7 million a year earlier.
Adjusted EBITDA was $24.3 million versus $33.5 million; North America same store sales decreased 7.5%.
2026 net new studio openings outlook is 124 to 130, versus previous guidance of approximately 150.
2026 adjusted EBITDA outlook narrowed to $91.0 million to $94.0 million from $91.0 million to $97.0 million; the strategic review, announced in April and supported by Jefferies, may result in a sale of the company.
Liberty Media reported third-quarter 2026 results with higher revenue, operating income and Adjusted OIBDA than in the same quarter of 2025, helped by one more Formula 1 race. Nine-month revenue was flat at $2.9 billion, and MotoGP results fell because it held two fewer races. The company also said its exchange of Dr. John Malone's high-vote Series B shares closed on November 4, reducing his voting power to about 3%.
Q3 2026 revenue was $1.2 billion, up from $1,085 million; operating income was $237 million, up from $158 million.
Q3 Adjusted OIBDA was $353 million versus $297 million; net earnings attributable to Liberty stockholders were $163 million versus $13 million.
Nine-month revenue was $2.9 billion, flat year over year, and nine-month operating income was $389 million versus $371 million.
The Malone share exchange closed November 4, 2026; his aggregate voting power fell to approximately 3%.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.